Answer:
who is anna , and how would i know did was anna a real person and is she dead
Explanation:
Answer:
apply oxygen via nonrebreathing mask, start an IV with normal saline, and administer 1 mg of epinephrine 1:10,000 via IV push
Growth delays
When giving methylphenidate to nursing patients, monitoring appetite suppression or growth delays is important. Methylphenidate is a member of the stimulant class of medications. They function by raising brain activity, particularly in regions that aid with attention and behavior regulation.
In order to treat children with attention deficit hyperactivity disorder, methylphenidate is employed (ADHD). They can focus better and it aids with hyperactivity and impulsive conduct. Additionally, people with ADHD or narcolepsy are treated with it (a sleep disorder).
Only prescriptions are accepted for methylphenidate. It is available as early release or prolonged release pills and capsules. To assist their ADHD, some kids might require both prolonged and rapid release methylphenidate.
Here's another question with an answer similar to this about attention deficit hyperactivity disorder (adhd): brainly.com/question/4099245
#SPJ4
Answer:
It is time to treat your patient. Your goal is to return her arterial blood oxygen to normal. Use the time and side effect information to drag and drop the treatments to be used first, second and third. Treatment Options 1. Diuretic by Injection 2. Oxygen by Nose 3. Corticosteroids by Nebulizer
Explanation:
Answer:
b) blastic red blood cell (RBC).
Explanation:
In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell <u>(RBC) alloantigens</u> in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology.
